E Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

E Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.69M	Buy	11,455 +639	+6%	+$283K	0.13%	83
2026 Q1	$4.83M	Buy	+10,816	New	+$5.04M	0.14%	85
2025 Q2	$4.29M	Sell	9,628 -256	-3%	-$118K	0.2%	71
2025 Q1	$4.79M	Buy	9,884 +3,448	+54%	+$1.61M	0.23%	66
2024 Q4	$2.59M	Buy	6,436 +1,031	+19%	+$478K	0.13%	95
2024 Q3	$2.51M	Buy	5,405 +115	+2%	+$55.2K	0.13%	80
2024 Q2	$2.48M	Buy	5,290 +1,061	+25%	+$461K	0.14%	72
2024 Q1	$1.77M	Sell	4,229 -122	-3%	-$51.6K	0.11%	80
2023 Q4	$1.77M	Sell	4,351 -78	-2%	-$28.8K	0.11%	59
2023 Q3	$1.54M	Buy	4,429 +438	+11%	+$153K	0.12%	62
2023 Q2	$1.4M	Sell	3,991 -459	-10%	-$155K	0.11%	60
2023 Q1	$1.4M	Sell	4,450 -180	-4%	-$54K	0.1%	70
2022 Q4	$1.34M	Sell	4,630 -7,018	-60%	-$2.14M	0.11%	71
2022 Q3	$3.37M	Buy	11,648 +6,592	+130%	+$1.9M	0.31%	39
2022 Q2	$1.43M	Buy	5,056 +539	+12%	+$144K	0.13%	73
2022 Q1	$1.18M	Buy	4,517 +99	+2%	+$23.5K	0.04%	80
2021 Q4	$970K	Sell	4,418 -168	-4%	-$32.7K	0.03%	111
2021 Q3	$832K	Buy	+4,586	New	+$895K	0.03%	97
2021 Q1	$895K	Buy	+4,165	New	+$915K	0.07%	94

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

E Fund Management's VRTX Position: Q2 2026 in Review

E Fund Management increased its Vertex Pharmaceuticals (VRTX) stake by 5.9% in Q2 2026, buying an estimated $283K and bringing the position to 11,455 shares worth $5.69M. The position accounts for 0.13% of the portfolio, ranked #83.

E Fund Management first reported a position in VRTX in Q1 2021 and has held it in 19 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

E Fund Management held 11,455 shares of Vertex Pharmaceuticals worth $5.69M as of Q2 2026.
E Fund Management bought 639 Vertex Pharmaceuticals shares in Q2 2026, an estimated $283K.
Vertex Pharmaceuticals made up 0.13% of E Fund Management's portfolio in Q2 2026, its #83 holding.
E Fund Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 19 quarters since.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.